Efficacy reports of Sputnik V vaccine for Covid-19 show 91.4% efficacy from a second interim analysis of more than 18,000 people.- Gamaleya National Center of Epidemiology and Microbiology.

Developers of Russia’s Sputnik V vaccine reported 91.4% efficacy from a second interim analysis of more than 18,000 people, bolstering a claim the team made on 11 November with little evidence. Whereas the initial report rested on a mere 20 cases of COVID-19, with no details on how they were split between vaccinated and placebo groups, the new analysis is based on 39 cases total, eight among the vaccinated group versus 31 in the much smaller placebo arm. Russia is preparing its Sputnik V coronavirus vaccine for launch in international markets from January 2021, with the promise of 500 million doses made available to foreign governments at around $10 a dose. Development of Sputnik V is conducted by The Gamaleya National Center of Epidemiology and Microbiology.